Modulation of the CFTR gene splicing for treatment of CF Project ID : 26-2016-4370
Investment Opportunities in Startups and Spinoffs
Modulation of the CFTR gene splicing for treatment of CF
Project ID : 26-2016-4370
Splisense is developing targeted therapies for genetic diseases based on splicing modulation treating the underlying root cause of the disease.
SpliSense’s initial focus is on Cystic Fibrosis. SpliSense is developing a new class of therapies which treat the underlying genetic cause of the disease, leading to the production of a normal protein.